CervoMed (NASDAQ:CRVO) was upgraded by analysts at Brookline Cap M to a "strong-buy" rating.
CervoMed (NASDAQ:CRVO) was upgraded by analysts at Brookline Capital Management to a "strong-buy" rating.
CervoMed (NASDAQ:CRVO) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $25.00 price target on the stock.
CervoMed (NASDAQ:CRVO) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating on the stock.
CervoMed Announces Late-Breaking Data at the 18th CTAD Conference Demonstrating Neflamapimod Significantly Slows Clinical Progression in Dementia with Lewy Bodies